E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.

ABSTRACT:

Lessons learned

Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer.Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a clinical trial.Improvements in biomarker development would be useful in developing future clinical trials in NET to better tailor individualized therapies and assess for possible efficacy endpoints.

Background

Neuroendocrine tumors (NETs) are rare malignancies of the gastrointestinal (GI) tract that are highly vascularized and overexpress vascular-endothelial growth factor (VEGF). Sunitinib has demonstrated efficacy in the pancreatic subset of NET. This study explored the activity of a

SUBMITTER: Lubner S 

PROVIDER: S-EPMC6192662 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature